ImmunoPrecise Antibodies Ltd.

As of June 13, 2025, the trend is bullish with moderate strength, supported by a bullish MACD and moving averages, although the weekly RSI indicates some short-term weakness.

As of March 2022, the management team of ImmunoPrecise Antibodies Ltd. includes Independent Chairman Mr. James Kuo, President and CEO Ms. Jennifer Bath, and several Independent Directors: Mr. Paul Andreola, Mr. Robert Beecroft, Mr. Robert Burke, Mr. Brian Lundstrom, and Mr. Greg Smith.

ImmunoPrecise Antibodies Ltd. is a Canadian micro-cap company specializing in custom hybridoma development services for the Pharmaceuticals & Biotechnology industry. As of January 2025, it reported net sales of $4 million and a net loss of $15 million, with a market cap of $43.31 million.

As of Jun 18, ImmunoPrecise Antibodies Ltd. has a market capitalization of 43.31 million and reported net sales of 17.42 million with a net profit of -33.23 million over the latest four quarters.